PS
REGN icon

Pinney & Scofield’s Regeneron Pharmaceuticals REGN Stock Holding History

Pinney & Scofield’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-35
Closed -$27K – 240
2026
Q1 		$27K Hold
35
– – 0.01% 148
2025
Q4 		$27K Hold
35
– – 0.02% 135
2025
Q3 		$19.7K Hold
35
– – 0.01% 148
2025
Q2 		$18.4K Hold
35
– – 0.01% 150
2025
Q1 		$22.2K Hold
35
– – 0.02% 136
2024
Q4 		$24.9K Buy
+35
New +$29.4K 0.02% 133

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Pinney & Scofield's REGN Position: Q2 2026 in Review

Pinney & Scofield sold out of Regeneron Pharmaceuticals (REGN) in Q2 2026, closing a stake of 35 shares — an estimated $27K sold.

Pinney & Scofield first reported a position in REGN in Q4 2024 and held it in 6 quarters. The position peaked at $27K in Q1 2026. 1,333 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • Pinney & Scofield reported no remaining Regeneron Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
  • Pinney & Scofield sold 35 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $27K.
  • Pinney & Scofield first reported a position in Regeneron Pharmaceuticals in Q4 2024 and held it in 6 quarters.
  • Pinney & Scofield's Regeneron Pharmaceuticals position peaked at $27K in Q1 2026.
  • 1,333 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on Pinney & Scofield's 13F filing for Q2 2026, filed 7 Aug 2026.